Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

New

Anti-PD-1 (Nivolumab) Biotinylated Antibody

Mouse monoclonal antibody to detect biotinylated PD-1 in human samples
Catalog #: A2117
SKU-Size Size Price Qty
A2117-30T 30 μl
$105.00
A2117-100 100 μl
$290.00
More Sizes Get Quote

Product Details

Antibody Target PD-1
Host Human
Antibody Type Monoclonal
Isotype IgG4
Immunogen Human programmed cell death 1 receptor (PD1)
Accession # Q02242
Gene ID 18566
Appearance Colorless liquid
Formulation In PBS, pH 7.2, 30% glycerol, 0.5% BSA, 0.5 mM EDTA and 0.03% proclin
Purification Affinity purified
Species Reactivity Human
Application ELISA
Application & Usage ELISA 1 µg
Handling The antibody solution should be gently mixed before use.
Storage Conditions -20ºC
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

Nivolumab, trade name Opdivo, is a medication used to treat cancer. It is used as a first line treatment for inoperable or metastatic melanoma in combination with Iplimumab if the cancer does not have a mutation in BRAF, as a second-line treatment following treatment with Iplimumab and if the cancer has a mutation in BRAF, with a BRAF inhibitor, as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.